Budget Impact Analysis of Volanesorsen as a Complement to the Diet in Adult Patients with Familial Chylomicronemia Syndrome (FCS) in Mexico
Author(s)
Laura J. Peralta, BSMA1, Emmanuel Martínez Samano, BSC1, Victor E. Martinez, MES1, Bertha E. Mancilla, MHE2, FERNANDO KARAM VARGAS, MBA2, Herman Soto, Sr., MSc1;
1HS ESTUDIOS FARMACOECONOMICOS, MEXICO CITY, Mexico, 2PTC THERAPEUTICS, MEXICO CITY, Mexico
1HS ESTUDIOS FARMACOECONOMICOS, MEXICO CITY, Mexico, 2PTC THERAPEUTICS, MEXICO CITY, Mexico
OBJECTIVES: Evaluate the budget impact of incorporating volanesorsen as a treatment in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and a high risk of pancreatitis, in whom the response to diet and triglyceride-lowering treatment has been insufficient from the perspective of the public health sector in Mexico.
METHODS: The budget impact analysis (BIA) was conducted over a five-year horizon (2024-2028). The target population was estimated using epidemiological data reported in the literature and validated by a panel of experts. A comparison of two scenarios was carried out: the current scenario considering standard therapy. The new scenario includes the incorporation of volanesorsen as a treatment option through a market penetration rate. The difference in both expenses represents the budgetary impact. Direct medical costs related to drug treatment, standard therapy, and the cost associated with acute pancreatitis events were considered through a local perspective. The results are expressed in dollars USD using the 2024 exchange rate ($18.32 MXN to 1 USD at the time of the analysis).
RESULTS: The incorporation of volanesorsen represents an investment of $519,000 by 2024; and $346,000 by 2028. This represents a decrease of 40%, of the public health sector's drug budget in Mexico. On average the estimated budgetary impact is $385,000, equating to 0.008%.
CONCLUSIONS: The inclusion of volanesorsen in the public health sector in Mexico increases the therapeutic options available for patients with FCS. Given the low prevalence of this disease, the results of the analysis indicate that its incorporation is economically viable, representing a reasonable investment to address an uncovered clinical condition.
METHODS: The budget impact analysis (BIA) was conducted over a five-year horizon (2024-2028). The target population was estimated using epidemiological data reported in the literature and validated by a panel of experts. A comparison of two scenarios was carried out: the current scenario considering standard therapy. The new scenario includes the incorporation of volanesorsen as a treatment option through a market penetration rate. The difference in both expenses represents the budgetary impact. Direct medical costs related to drug treatment, standard therapy, and the cost associated with acute pancreatitis events were considered through a local perspective. The results are expressed in dollars USD using the 2024 exchange rate ($18.32 MXN to 1 USD at the time of the analysis).
RESULTS: The incorporation of volanesorsen represents an investment of $519,000 by 2024; and $346,000 by 2028. This represents a decrease of 40%, of the public health sector's drug budget in Mexico. On average the estimated budgetary impact is $385,000, equating to 0.008%.
CONCLUSIONS: The inclusion of volanesorsen in the public health sector in Mexico increases the therapeutic options available for patients with FCS. Given the low prevalence of this disease, the results of the analysis indicate that its incorporation is economically viable, representing a reasonable investment to address an uncovered clinical condition.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE481
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Rare & Orphan Diseases